-$0.09 EPS Expected for Avid Bioservices Inc (CDMO) This Quarter

Share on StockTwits

Analysts predict that Avid Bioservices Inc (NASDAQ:CDMO) will report earnings of ($0.09) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Avid Bioservices’ earnings. The highest EPS estimate is ($0.01) and the lowest is ($0.16). Avid Bioservices reported earnings per share of ($0.06) in the same quarter last year, which would suggest a negative year-over-year growth rate of 50%. The company is expected to issue its next earnings report after the market closes on Monday, September 10th.

On average, analysts expect that Avid Bioservices will report full-year earnings of ($0.20) per share for the current financial year, with EPS estimates ranging from ($0.33) to ($0.03). For the next financial year, analysts anticipate that the firm will report earnings of $0.02 per share, with EPS estimates ranging from ($0.07) to $0.14. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Avid Bioservices.

Avid Bioservices (NASDAQ:CDMO) last posted its quarterly earnings results on Monday, July 16th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.20. The firm had revenue of $6.94 million for the quarter, compared to analysts’ expectations of $6.51 million. Avid Bioservices had a negative net margin of 40.68% and a negative return on equity of 58.67%.

A number of analysts have weighed in on CDMO shares. Zacks Investment Research cut shares of Avid Bioservices from a “hold” rating to a “sell” rating in a report on Thursday, July 19th. ValuEngine raised shares of Avid Bioservices from a “hold” rating to a “buy” rating in a report on Thursday, August 30th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Avid Bioservices in a report on Tuesday, July 17th. Finally, Janney Montgomery Scott started coverage on shares of Avid Bioservices in a report on Monday, June 25th. They set a “buy” rating and a $10.00 target price on the stock. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $7.50.

CDMO opened at $7.04 on Thursday. The firm has a market capitalization of $409.85 million, a P/E ratio of -14.08 and a beta of 2.33. Avid Bioservices has a 12-month low of $2.24 and a 12-month high of $7.33.

Several large investors have recently modified their holdings of CDMO. Comerica Bank acquired a new stake in shares of Avid Bioservices during the first quarter worth $131,000. Commonwealth Equity Services LLC bought a new position in shares of Avid Bioservices during the first quarter worth about $156,000. Rhumbline Advisers bought a new position in shares of Avid Bioservices during the second quarter worth about $174,000. Citadel Advisors LLC bought a new position in shares of Avid Bioservices during the first quarter worth about $190,000. Finally, California Public Employees Retirement System bought a new position in shares of Avid Bioservices during the first quarter worth about $200,000. 21.72% of the stock is currently owned by institutional investors.

Avid Bioservices Company Profile

Avid Bioservices, Inc, a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

Featured Article: What is a Stop Order?

Get a free copy of the Zacks research report on Avid Bioservices (CDMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avid Bioservices (NASDAQ:CDMO)

Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply